TMO
Thermo Fisher Scientific Inc.
Diagnostics & Research · Healthcare · United States
709.18
close · 2026-10-29
value
58
cheaper than peers58
quality
62
stronger fundamentals62
ranked against
Diagnostics & Research
value
quality
31 peers
Value inputs
| measure | company | vs peers |
| forward P/E | 25.55× | 73 |
| price to book | 4.79× | 57 |
| EV to EBITDA | 24.94× | 50 |
| price to sales | 5.54× | 47 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 18.8% | 78 |
| return on equity | 13.5% | 71 |
| revenue growth | 10.5% | 50 |
| debt to equity | 80.6% | 33 |
4 of 4 measures available
Facts
| market cap | $262B |
| free cash flow | $6.24B |
| employees | 125,000 |
| first trade | 1980-03-17 |
| next earnings | 2026-10-21 |
| fundamentals updated | 2026-10-21 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 17.74 | 16.53 | 15.45 | 17.63 |
| free cash flow | $6.29B | $7.27B | $6.93B | $6.91B |
| net income | $6.70B | $6.33B | $6.00B | $6.95B |
| revenue | $44.56B | $42.88B | $42.86B | $44.91B |
| unusual items | -$349.0M | -$358.0M | -$505.0M | -$275.0M |